124 related articles for article (PubMed ID: 38381443)
1. Matching Drug Prices to Their Clinical Benefit-The Final Frontier?
Wilson ECF; Yiu ZZN
JAMA Dermatol; 2024 Apr; 160(4):387-388. PubMed ID: 38381443
[No Abstract] [Full Text] [Related]
2. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
[TBL] [Abstract][Full Text] [Related]
3. [Pharmaceutical pricing; what is reasonable?].
Versteegh MM
Ned Tijdschr Geneeskd; 2020 Aug; 164():. PubMed ID: 32940991
[TBL] [Abstract][Full Text] [Related]
4. [The Probabilistic Efficiency Frontier: A Value Assessment of Treatment Options in Hepatitis C].
Mühlbacher AC; Sadler A
Gesundheitswesen; 2019 Jan; 81(1):e21-e32. PubMed ID: 28628931
[TBL] [Abstract][Full Text] [Related]
5. Expected net benefit of clinical pharmacy in intensive care medicine: a randomized interventional comparative trial with matched before-and-after groups.
Claus BO; Robays H; Decruyenaere J; Annemans L
J Eval Clin Pract; 2014 Dec; 20(6):1172-9. PubMed ID: 25470782
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
[TBL] [Abstract][Full Text] [Related]
7. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time.
Saluja R; Arciero VS; Cheng S; McDonald E; Wong WWL; Cheung MC; Chan KKW
J Oncol Pract; 2018 May; 14(5):e280-e294. PubMed ID: 29601250
[TBL] [Abstract][Full Text] [Related]
8. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.
Trotta F; Mayer F; Barone-Adesi F; Esposito I; Punreddy R; Da Cas R; Traversa G; Perrone F; Martini N; Gyawali B; Addis A
BMJ Open; 2019 Dec; 9(12):e033728. PubMed ID: 31826897
[TBL] [Abstract][Full Text] [Related]
9. [Cost/benefit analysis of cancer drugs].
Jordan B
Med Sci (Paris); 2020 Nov; 36(11):1095-1097. PubMed ID: 33151876
[TBL] [Abstract][Full Text] [Related]
10. The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data.
Schöttler MH; Coerts FB; Postma MJ; Boersma C; Rozenbaum MH
Value Health; 2023 Jan; 26(1):91-98. PubMed ID: 35933271
[TBL] [Abstract][Full Text] [Related]
11. Good reasons for confidential drug prices.
Østby JT; Solli O
Tidsskr Nor Laegeforen; 2019 Mar; 139(5):. PubMed ID: 30872829
[No Abstract] [Full Text] [Related]
12. A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency.
Gandjour A
BMC Health Serv Res; 2020 Mar; 20(1):240. PubMed ID: 32293433
[TBL] [Abstract][Full Text] [Related]
13. Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Reports.
Bloudek LM; Nguyen V; Grueger J; Sullivan SD
Value Health; 2021 Jun; 24(6):789-794. PubMed ID: 34119076
[TBL] [Abstract][Full Text] [Related]
14. [High prices and low clinical benefit: anomalies of the drug market].
Pagano E
Epidemiol Prev; 2018; 42(1):92-93. PubMed ID: 29506372
[No Abstract] [Full Text] [Related]
15. The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017.
Rodwin MA; Mancini J; Duran S; Jalbert AC; Viens P; Maraninchi D; Gonçalves A; Marino P
Eur J Cancer; 2021 Mar; 145():11-18. PubMed ID: 33412466
[TBL] [Abstract][Full Text] [Related]
16. Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.
Hill A; Redd C; Gotham D; Erbacher I; Meldrum J; Harada R
BMJ Open; 2017 Jan; 7(1):e011965. PubMed ID: 28110283
[TBL] [Abstract][Full Text] [Related]
17. Should drug prices be negotiated under part D of Medicare? And if so, how?
Frank RG; Newhouse JP
Health Aff (Millwood); 2008; 27(1):33-43. PubMed ID: 18180478
[TBL] [Abstract][Full Text] [Related]
18. Patient Population Size And Drug Prices.
Liang X
Health Aff (Millwood); 2019 Aug; 38(8):1409. PubMed ID: 31381408
[No Abstract] [Full Text] [Related]
19. When will the U.S. flinch at cancer drug prices?
Vanchieri C
J Natl Cancer Inst; 2005 May; 97(9):624-6. PubMed ID: 15870428
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder.
Rendas-Baum R; Yang M; Gricar J; Wallenstein GV
Appl Health Econ Health Policy; 2010; 8(2):129-40. PubMed ID: 20175591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
